Stay updated with breaking news from Telix Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an
A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it...
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): Primary endpoint met: Sensitivity of 84% and specificity of 84% in all three readers (86% / 87% overall) Considerably exceeds confirmatory trial sensitivity and specificity success targets Key secondary endpoints met, achieving 85% sensitivity and 89% specificity in small renal masses (cT1a 4cm) Full data set: 93% positive predictive val...